Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05027048 · ClinicalTrials.gov registry record · Phase 3
Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery
A Phase 3 study of Postpartum Hemorrhage and Cesarean Section Complications, sponsored by Stanford University.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT05027048 is a Phase 3 study of Postpartum Hemorrhage and Cesarean Section Complications that has completed, run by Stanford University. The registered enrollment target is 120 participants, below the 194-participant average among 11 other Postpartum Hemorrhage trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05027048, a Phase 3 study of Postpartum Hemorrhage and Cesarean Section Complications, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
Postpartum hemorrhage (PPH) is the leading cause of maternal morbidity and mortality worldwide. Up to 80% of PPH is caused by uterine atony, the failure of the uterine smooth muscle to contract and compress the uterine vasculature after delivery. Laboratory and epidemiological studies show that low extracellular and serum calcium levels, respectively, decrease uterine contractility. A pilot study performed by the investigators supports the hypothesis that intravenous calcium chloride is well tolerated and may have utility in preventing uterine atony. The proposed research will establish the relationship between uterine tone and calcium through a clinical trial with an incorporated pharmacokinetic and pharmacodynamic (PK/PD) study. In a randomized, placebo-controlled, double-blind trial, investigators will establish the effect of 1 gram of intravenous calcium chloride upon quantitative blood loss and uterine tone during cesarean delivery in parturients with high risk of uterine atony. Investigators will concurrently collect serial venous blood samples to measure calcium for PK/PD modeling in this pregnant study cohort. High-quality clinical research and development of novel therapeutics to manage uterine atony are critical to reduce the high maternal morbidity and mortality from PPH.
Conditions Studied
Interventions
- DRUG Saline placebo
- DRUG Calcium chloride
Study Locations (1)
California
- Jessica Ansari - Pacifica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2022-04-04 |
| Est. Completion | 2023-04-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05027048
The ClinicalTrials.gov registry entry for NCT05027048 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 194-participant average among 11 other Postpartum Hemorrhage trials with a reported enrollment target (38% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Postpartum Hemorrhage appearing as the primary indexed condition, and to 2 interventions - of which Saline placebo is the first listed.
NCT05027048 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05027048 about?
NCT05027048 is a clinical study titled "Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery". Postpartum hemorrhage (PPH) is the leading cause of maternal morbidity and mortality worldwide. Up to 80% of PPH is caused by uterine atony, the failure of the uterine smooth muscle to contract and compress the uterine vasculature after delivery. Laboratory and epidemiological studies show that low ...
What is the current status of trial NCT05027048?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2022-04-04. Estimated completion is 2023-04-03.
What conditions does trial NCT05027048 study?
This clinical trial studies the following conditions: Postpartum Hemorrhage, Cesarean Section Complications, Uterine Atony, Uterine Atony With Hemorrhage.
What interventions are being tested in trial NCT05027048?
The interventions under investigation include: Saline placebo (DRUG), Calcium chloride (DRUG).
Who is sponsoring clinical trial NCT05027048?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05027048 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postpartum Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
RECRUITING · Phase 3
-
Safety and Effectiveness of the KOKO Device to Treat Primary Abnormal Postpartum Uterine Bleeding or Hemorrhage
RECRUITING · NA
-
Postpartum Oxytocin Administration in the Era of Delayed Cord Clamping
COMPLETED · NA
-
A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects
COMPLETED · Phase 1
-
Prophylactic Methylergonovine for Twin Cesarean
COMPLETED · Phase 4
-
Prospective Effect of Intravenous Ketorolac on Opioid Use, EBL and Complications Following Cesarean Delivery
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.